320 related articles for article (PubMed ID: 38067319)
1. Clonal Neoantigen: Emerging "Mechanism-based" Biomarker of Immunotherapy Response.
Nemunaitis J; Stanbery L; Willoughby D; Bognar E; Brun S; Walter A; Monk BJ; Rocconi RP; Choucair K; Coleman RL
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067319
[TBL] [Abstract][Full Text] [Related]
2. Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
Walter A; Rocconi RP; Monk BJ; Herzog TJ; Manning L; Bognar E; Wallraven G; Aaron P; Horvath S; Tang M; Stanbery L; Coleman RL; Nemunaitis J
Gynecol Oncol; 2021 Dec; 163(3):459-464. PubMed ID: 34702567
[TBL] [Abstract][Full Text] [Related]
3. Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
Rocconi RP; Monk BJ; Walter A; Herzog TJ; Galanis E; Manning L; Bognar E; Wallraven G; Stanbery L; Aaron P; Senzer N; Coleman RL; Nemunaitis J
Gynecol Oncol; 2021 Jun; 161(3):676-680. PubMed ID: 33715892
[TBL] [Abstract][Full Text] [Related]
4. Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy.
Sliheet E; Robinson M; Morand S; Choucair K; Willoughby D; Stanbery L; Aaron P; Bognar E; Nemunaitis J
Cancer Gene Ther; 2022 Jul; 29(7):993-1000. PubMed ID: 34785763
[TBL] [Abstract][Full Text] [Related]
5. ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer.
Rocconi RP; Stanbery L; Tang M; Walter A; Monk BJ; Herzog TJ; Coleman RL; Manning L; Wallraven G; Horvath S; Bognar E; Senzer N; Brun S; Nemunaitis J
Commun Med (Lond); 2022; 2():106. PubMed ID: 36051466
[TBL] [Abstract][Full Text] [Related]
6. Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies.
Lo AA; Wallace A; Oreper D; Lounsbury N; Havnar C; Pechuan-Jorge X; Wu TD; Bourgon R; Jones R; Krogh K; Yang GY; Zill OA
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599029
[TBL] [Abstract][Full Text] [Related]
7. Cancer neoantigens as potential targets for immunotherapy.
Ma W; Pham B; Li T
Clin Exp Metastasis; 2022 Feb; 39(1):51-60. PubMed ID: 33950415
[TBL] [Abstract][Full Text] [Related]
8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
9. Construction and validation of an immunoediting-based optimized neoantigen load (ioTNL) model to predict the response and prognosis of immune checkpoint therapy in various cancers.
Su X; Jin H; Wang J; Lu H; Gu T; Gao Z; Li M
Aging (Albany NY); 2022 May; 14(10):4586-4605. PubMed ID: 35613927
[TBL] [Abstract][Full Text] [Related]
10. Profiling of hepatocellular carcinoma neoantigens reveals immune microenvironment and clonal evolution related patterns.
Li Z; Chen G; Cai Z; Dong X; He L; Qiu L; Zeng Y; Liu X; Liu J
Chin J Cancer Res; 2021 Jun; 33(3):364-378. PubMed ID: 34321833
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition.
Litchfield K; Reading JL; Puttick C; Thakkar K; Abbosh C; Bentham R; Watkins TBK; Rosenthal R; Biswas D; Rowan A; Lim E; Al Bakir M; Turati V; Guerra-Assunção JA; Conde L; Furness AJS; Saini SK; Hadrup SR; Herrero J; Lee SH; Van Loo P; Enver T; Larkin J; Hellmann MD; Turajlic S; Quezada SA; McGranahan N; Swanton C
Cell; 2021 Feb; 184(3):596-614.e14. PubMed ID: 33508232
[TBL] [Abstract][Full Text] [Related]
12. Measuring Tumor Mutational Burden Using Whole-Exome Sequencing.
Vilimas T
Methods Mol Biol; 2020; 2055():63-91. PubMed ID: 31502147
[TBL] [Abstract][Full Text] [Related]
13. The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.
Sholl LM; Hirsch FR; Hwang D; Botling J; Lopez-Rios F; Bubendorf L; Mino-Kenudson M; Roden AC; Beasley MB; Borczuk A; Brambilla E; Chen G; Chou TY; Chung JH; Cooper WA; Dacic S; Lantuejoul S; Jain D; Lin D; Minami Y; Moreira A; Nicholson AG; Noguchi M; Papotti M; Pelosi G; Poleri C; Rekhtman N; Tsao MS; Thunnissen E; Travis W; Yatabe Y; Yoshida A; Daigneault JB; Zehir A; Peters S; Wistuba II; Kerr KM; Longshore JW
J Thorac Oncol; 2020 Sep; 15(9):1409-1424. PubMed ID: 32522712
[TBL] [Abstract][Full Text] [Related]
14. The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space.
Lau TTY; Sefid Dashti ZJ; Titmuss E; Pender A; Topham JT; Bridgers J; Loree JM; Feng X; Pleasance ED; Renouf DJ; Schrader KA; Sun S; Ho C; Marra MA; Laskin J; Karsan A
J Mol Diagn; 2022 Jun; 24(6):609-618. PubMed ID: 35367630
[TBL] [Abstract][Full Text] [Related]
15. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
[TBL] [Abstract][Full Text] [Related]
16. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
17. The Neoantigen Landscape of Mycosis Fungoides.
Sivanand A; Hennessey D; Iyer A; O'Keefe S; Surmanowicz P; Vaid G; Xiao Z; Gniadecki R
Front Immunol; 2020; 11():561234. PubMed ID: 33329522
[TBL] [Abstract][Full Text] [Related]
18. Tumour mutational burden: an overview for pathologists.
Doig KD; Fellowes A; Scott P; Fox SB
Pathology; 2022 Apr; 54(3):249-253. PubMed ID: 35153070
[TBL] [Abstract][Full Text] [Related]
19. The neoantigens derived from transposable elements - A hidden treasure for cancer immunotherapy.
Hu Z; Guo X; Li Z; Meng Z; Huang S
Biochim Biophys Acta Rev Cancer; 2024 Jun; 1879(5):189126. PubMed ID: 38849060
[TBL] [Abstract][Full Text] [Related]
20. Challenges targeting cancer neoantigens in 2021: a systematic literature review.
Chen I; Chen MY; Goedegebuure SP; Gillanders WE
Expert Rev Vaccines; 2021 Jul; 20(7):827-837. PubMed ID: 34047245
[No Abstract] [Full Text] [Related]
[Next] [New Search]
